Phathom Pharmaceuticals announced that the FDA has opened a public docket to solicit comments regarding legal challenges brought by BDR Pharmaceuticals against the FDA's decision to grant VOQUEZNA 10 years of New Chemical Entity (NCE) exclusivity. The litigation challenges the exclusivity period that currently protects VOQUEZNA through May 2032, and a second potential generic filer, Saba Ilac Sanayii Ve Ticaret AS, has also indicated intent to join the legal challenge.
BDR Pharmaceuticals has filed a lawsuit against the FDA challenging the agency's decision to grant Phathom's VOQUEZNA (vonoprazan) 10 years of NCE exclusivity through May 2032. BDR alleges the FDA improperly applied the GAIN Act to extend this exclusivity, which currently prevents the FDA from receiving abbreviated new drug applications (ANDAs) for generic versions of the drug. Phathom intends to take action to protect its statutory exclusivities and believes the FDA's prior ruling was correct.